Sequencing therapies for metastatic renal cell carcinoma

Basit Öğe Kaydı
dc.authorid0000-0002-8142-2875
dc.contributor.authorDizman, Nazlı
dc.contributor.authorArslan, Zeynep Ece
dc.contributor.authorFeng, Matthew
dc.contributor.authorPal, Sumanta K.
dc.date.accessioned2020-07-27T06:22:44Z
dc.date.available2020-07-27T06:22:44Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi
dc.description.abstractIn an era of several therapeutic options available, optimal treatment sequencing is crucial to providing patients the most effective therapy and promoting quality of life. In clear cell renal cell carcinoma, a combination approach with an immunotherapy backbone, such as nivolumab/ipilimumab or axitinib/pembrolizumab, has a key role in the first-line setting. Safety and activity data support the transition to single-agent targeted therapies in the second-line setting. Nivolumab monotherapy possesses clinical and mechanistic rationale as a second-line therapeutic option for patients treated with targeted therapies in the first-line setting. Gene expression models are being generated from large prospective clinical trial data sets.
dc.identifier.citationDizman, N., Arslan, Z. E., Feng, M. ve Pal, S. K. (2020). Sequencing therapies for metastatic renal cell carcinoma. Urologic Clinics of North America, 47(3), 305-318. https://dx.doi.org/10.1016/j.ucl.2020.04.008
dc.identifier.doi10.1016/j.ucl.2020.04.008
dc.identifier.endpage318
dc.identifier.issn0094-0143
dc.identifier.issn1558-318X
dc.identifier.issue3
dc.identifier.scopusqualityQ2
dc.identifier.startpage305
dc.identifier.urihttps://dx.doi.org/10.1016/j.ucl.2020.04.008
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5604
dc.identifier.volume47
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWB Saunders Co-Elsevier Inc.
dc.relation.ispartofUrologic Clinics of North Americaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectTargeted Therapy
dc.subjectImmunotherapy
dc.subjectSequencing
dc.subjectRCC
dc.subjectKidney Cancer
dc.titleSequencing therapies for metastatic renal cell carcinoma
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Arslan, Zeynep E.-2020.pdf
Boyut:
866.54 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu